iSpecimen Inc. Raises $1.75 Million Through At-Market Private Placement to Bolster Marketing and Corporate Purposes
ByAinvest
Wednesday, Aug 6, 2025 2:26 pm ET1min read
ISPC--
The funds raised will be used to bolster marketing efforts, with $500,000 allocated to marketing and advertising services through IR Agency LLC. The remaining $1.25 million will support working capital and general corporate purposes. WestPark Capital served as the exclusive placement agent for the offering, which closed on August 4, 2025 [2].
iSpecimen's platform connects scientists with healthcare providers, enabling efficient access to necessary biospecimens for medical research and discovery. The company's proprietary, cloud-based technology allows scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations [3].
The private placement was exclusively available to accredited investors and will require subsequent SEC registration for potential resale. Additional details regarding the offering will be available in a Form 8-K filing with the SEC [1].
References:
[1] https://www.globenewswire.com/news-release/2025/08/04/3126989/0/en/iSpecimen-Inc-Announces-Closing-of-Approximately-1-75-Million-Private-Placement-Priced-At-the-Market.html
[2] https://www.gurufocus.com/news/3023707/ispecimen-inc-announces-pricing-of-approximately-175-million-private-placement-priced-atthemarket-ispc-stock-news
[3] https://www.stocktitan.net/news/ISPC/i-specimen-inc-announces-closing-of-approximately-1-75-million-1ebr32zcwmw7.html
iSpecimen Inc. (ISPC) closed a $1.75 million private placement, issuing 1.56 million shares of common stock and pre-funded warrants at $1.122 each. Funds will bolster marketing efforts and general corporate purposes. WestPark Capital served as the exclusive placement agent. The transaction closed on August 4, 2025, and details will be disclosed in a Form 8-K filing with the SEC.
iSpecimen Inc. (ISPC), an online marketplace for human biospecimens, has successfully closed a $1.75 million private placement. The company issued 1,559,828 shares of common stock and pre-funded warrants at a price of $1.122 per share, aligning with Nasdaq's at-the-market pricing rules [1].The funds raised will be used to bolster marketing efforts, with $500,000 allocated to marketing and advertising services through IR Agency LLC. The remaining $1.25 million will support working capital and general corporate purposes. WestPark Capital served as the exclusive placement agent for the offering, which closed on August 4, 2025 [2].
iSpecimen's platform connects scientists with healthcare providers, enabling efficient access to necessary biospecimens for medical research and discovery. The company's proprietary, cloud-based technology allows scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations [3].
The private placement was exclusively available to accredited investors and will require subsequent SEC registration for potential resale. Additional details regarding the offering will be available in a Form 8-K filing with the SEC [1].
References:
[1] https://www.globenewswire.com/news-release/2025/08/04/3126989/0/en/iSpecimen-Inc-Announces-Closing-of-Approximately-1-75-Million-Private-Placement-Priced-At-the-Market.html
[2] https://www.gurufocus.com/news/3023707/ispecimen-inc-announces-pricing-of-approximately-175-million-private-placement-priced-atthemarket-ispc-stock-news
[3] https://www.stocktitan.net/news/ISPC/i-specimen-inc-announces-closing-of-approximately-1-75-million-1ebr32zcwmw7.html

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet